Although neurologists consider intravenous tissue plasminogen activator (tPA) to be standard of care in the treatment of patients with acute ischemic stroke, its use remains contentious within the broader medical community, and particularly among emergency physicians. Why might this be? We provide a historical context to this ongoing controversy by reviewing how neurologists have conceptualized the acute stroke and its treatment, with the aim of bridging this gap.
Methods:
Based on historical sources in the Mackie Family History of Neuroscience Collection at the University of Calgary, as well as online resources, we trace the evolution of the concept of the “acute stroke,” which has come to mean a stroke that is potentially treatable with tPA. We frame this conceptualization in relation to historical “building blocks” in anatomy, pathology, and physiology. We then use these building blocks to explain why neurologists understand tPA to be effective and why emergency physicians often do not.
Results and Conclusions:
Arguments against the use of tPA reiterate 20-year-old concerns about its efficacy and safety. We believe these persistent concerns can be framed as a lack of understanding of the “building blocks” upon which neurologists’ conception of tPA is built. Our view suggests that the way forward to bridge the gap between neurology and other disciplines is not to conduct more trials but to offer a shared conceptualization of the trials already completed and of the intellectual tradition from which they emerged.
The National Institute of Neurological Disorders and Stroke (NINDS) r-tPA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
4.
SilbergleitRScottPA. Thrombolysis for acute stroke: the incontrovertible, the controvertible and the uncertain. Acad Emerg Med. 2005;12(4):348–351.
5.
ChanY-FKwiatkowskiTGRellaJGRennieWPKnownRKSilvermanRA. Tissue plasminogen activator for acute ischemic stroke: a New York City emergency medicine perspective. J Emerg Med. 2005;29(4):405–408.
6.
ScottPAXuZMeurerWJ, et al.Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the Increasing Stroke Treatment though Interactive Behavioral Change Tactic (INSTINCT) trial hospitals. Stroke. 2010;41(9):2026–2032.
7.
MannJ. Emergency physician survey: recombinant tissue plasminogen activator for stroke. Ann Emerg Med. 2006;48(4):476.
8.
BrownDLBarsanWGLisabethLDGalleryMEMorgensternLB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.
9.
TemkinO.The Falling Sickness: A History of Epilepsy from the Greeks to the Beginnings of Modern Neurology. Baltimore, MD: Johns Hopkins University Press; 1994.
10.
DuffinJ. Lovers and Livers: Disease Concepts in History. 1st ed. Toronto, Ontario, Canada; Buffalo, NY: University of Toronto Press, Scholarly Publishing Division; 2005.
11.
PoundPBuryMEbrahimS. From apoplexy to stroke. Age Ageing. 1997;26(5):331–337.
12.
WillisT.The London practice of physick. In: Classics of Neurology & Neurosurgery Library. New York, NY: Gryphon: 1999.
13.
CookeJ. A Treatise on Nervous Diseases: Vol. I on Apoplexy. [Vol. II on Palsy and on Epilepsy.]. Boston, MA: Longman; 1820.
14.
SussmanBJFitchTS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA. 1958;167(14):1705–1709. doi:10.1001/jama.1958.02990310011002.
15.
HackeWKasteMFieschiC, et al.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245–1251.
16.
HackeWKasteMFieschiC, et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–1025. doi:10.1001/jama.1995.03530130023023.
17.
ClarkWMAlbersGWMaddenKPHamiltonS. The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 2000;31(4):811–816. doi:10.1161/01.STR.31.4.811.
18.
ClarkWMWissmanSAlbersGW, et al.Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. JAMA. 1999;282(21):2019–2026.
19.
HarveyWW. The Anatomical Lectures of William Harvey. Prelectiones Anatomie Universalis De Musculis. In: WhitteridgeG, ed. Edinburgh, Scotland: E. & S. Livingstone; 1964. Edited, with an Introduction, Translation and Notes By Gweneth Whitteridge.
20.
SchuttaHS. Morgagni on apoplexy in De Sedibus: a historical perspective. J Hist Neurosci. 2009;18(1):1–24. doi:10.1080/09647040701578219.
21.
EadieMJ. A pathology of the animal spirits—the clinical neurology of Thomas Willis (1621–1675) Part I—background, and disorders of intrinsically normal animal spirits. J Clin Neurosci. 2003;10(1):14–29. doi:10.1016/S0967-5868(02)00165-0.
22.
CollenDLijnenHR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost. 2004;(4):541–546. doi:10.1111/j.1538-7933.2004.00645.x.
23.
RowlandLP. NINDS at 50: An Incomplete History Celebrating the Fiftieth Anniversary of the National Institute of Neurological Disorders and Stroke. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2001.
24.
NogueiraRGJadhavAPHaussenDC, et al.Thrombectomy 6 to 24 Hours after Stroke with a mismatch between deficit and infarct. NEJM. 2018;378(1):11–21. doi:10.1056/NEJMoa1706442.
25.
LenzerJWarlowCSaverJLKidwellCSStarkmanS. Alteplase for stroke: money and optimistic claims buttress the “Brain Attack” campaign. BMJ. 2002;324(7339):723–729.
26.
CasaubonLKBoulangerJMBlacquiereD, et al.Canadian stroke best practice recommendations: hyperacute stroke care guidelines, Update 2015. Int J Stroke. 2015;10(6):924–940. doi:10.1111/ijs.12551.
27.
RuddAGBowenAYoungGRJamesMA. The latest national clinical guideline for stroke. Clin Med. 2017;17(2):154–155. doi:10.7861/clinmedicine.17-2-154.
